Study | Population | Sample Size | All Doses, HCQ (mg/l), Mean (SD) | 400-mg Dose, HCQ (mg/l), Mean (SD) | Target Plasma HCQ (mg/l), EC50 0.72 uM |
---|---|---|---|---|---|
Balevic15 (serum) | Pregnant adults, rheumatic diseases (North America) | 50 | 0.305–0.424 (0.193–0.261) | 0.319–0.441 (0.195–0.281) | |
Balevic (serum) | Children, SLE (North America) | 131 | Baseline: 0.3 (0.229); 12–month: 0.287 (0.211) | NA | 0.48 |
Morita13 (plasma) | Adults, cutaneous or SLE (Japan) | 90 | 0.136–0.197 (0.045–0.079) | 0.192 (0.046) | |
Mok14 (serum) | Adults, SLE (China) | 276 | 0.202–0.437 (0.152–0.281) | 0.437 (0.281) |
EC50: half-maximal effective concentrations; SLE: systemic lupus erythematosus; NA: not applicable.